These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 36344069)
21. Interleukin-17 Pathophysiology and Therapeutic Intervention in Cystic Fibrosis Lung Infection and Inflammation. Hsu D; Taylor P; Fletcher D; van Heeckeren R; Eastman J; van Heeckeren A; Davis P; Chmiel JF; Pearlman E; Bonfield TL Infect Immun; 2016 Sep; 84(9):2410-21. PubMed ID: 27271746 [TBL] [Abstract][Full Text] [Related]
22. Cystic Fibrosis: Pathophysiology of Lung Disease. Bergeron C; Cantin AM Semin Respir Crit Care Med; 2019 Dec; 40(6):715-726. PubMed ID: 31659725 [TBL] [Abstract][Full Text] [Related]
23. Current evidence on the effect of highly effective CFTR modulation on interleukin-8 in cystic fibrosis. Williamson M; Casey M; Gabillard-Lefort C; Alharbi A; Teo YQJ; McElvaney NG; Reeves EP Expert Rev Respir Med; 2022 Jan; 16(1):43-56. PubMed ID: 34726115 [TBL] [Abstract][Full Text] [Related]
24. Pseudomonas aeruginosa infection, but not mono or dual-combination CFTR modulator therapy affects circulating regulatory T cells in an adult population with cystic fibrosis. Westhölter D; Beckert H; Straßburg S; Welsner M; Sutharsan S; Taube C; Reuter S J Cyst Fibros; 2021 Nov; 20(6):1072-1079. PubMed ID: 34030985 [TBL] [Abstract][Full Text] [Related]
25. Pharmacotherapy of the ion transport defect in cystic fibrosis: role of purinergic receptor agonists and other potential therapeutics. Kunzelmann K; Mall M Am J Respir Med; 2003; 2(4):299-309. PubMed ID: 14719996 [TBL] [Abstract][Full Text] [Related]
30. The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy. Lommatzsch ST; Taylor-Cousar JL Ther Adv Respir Dis; 2019; 13():1753466619844424. PubMed ID: 31027466 [TBL] [Abstract][Full Text] [Related]
35. Anti-inflammatories and mucociliary clearance therapies in the age of CFTR modulators. Perrem L; Ratjen F Pediatr Pulmonol; 2019 Nov; 54 Suppl 3():S46-S55. PubMed ID: 31715088 [TBL] [Abstract][Full Text] [Related]
36. New insights into the pathogenesis of cystic fibrosis sinusitis. Chang EH Int Forum Allergy Rhinol; 2014 Feb; 4(2):132-7. PubMed ID: 24282147 [TBL] [Abstract][Full Text] [Related]
37. Improving outcomes of infections in cystic fibrosis in the era of CFTR modulator therapy. Saiman L Pediatr Pulmonol; 2019 Nov; 54 Suppl 3():S18-S26. PubMed ID: 31715086 [TBL] [Abstract][Full Text] [Related]
38. Impact of Meoli A; Eickmeier O; Pisi G; Fainardi V; Zielen S; Esposito S Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293274 [TBL] [Abstract][Full Text] [Related]
39. Iron chelation as novel treatment for lung inflammation in cystic fibrosis. Aali M; Caldwell A; House K; Zhou J; Chappe V; Lehmann C Med Hypotheses; 2017 Jul; 104():86-88. PubMed ID: 28673599 [TBL] [Abstract][Full Text] [Related]
40. Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections. Hisert KB; Heltshe SL; Pope C; Jorth P; Wu X; Edwards RM; Radey M; Accurso FJ; Wolter DJ; Cooke G; Adam RJ; Carter S; Grogan B; Launspach JL; Donnelly SC; Gallagher CG; Bruce JE; Stoltz DA; Welsh MJ; Hoffman LR; McKone EF; Singh PK Am J Respir Crit Care Med; 2017 Jun; 195(12):1617-1628. PubMed ID: 28222269 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]